Cambium Bio Limited (ASX:CMB)
Australia · Delayed Price · Currency is AUD 0.2800
+0.0050 (1.82%)
At close: Jul 18, 2025, 4:00 PM AEST
Cambium Bio Company Description
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications.
Its lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus for wound healing indications.
Cambium Bio Limited is based in Paddington, Australia.
Cambium Bio Limited
| Country | Australia |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Karolis Rosickas |
Contact Details
Address: 16 Goodhope Street Paddington, 2021 Australia | |
| Phone | 61 13 0099 5098 |
| Website | cambium.bio |
Stock Details
| Ticker Symbol | CMB |
| Exchange | Australian Securities Exchange |
| Reporting Currency | AUD |
| ISIN Number | AU000000RGS6 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Karolis Rosickas M.B.A., M.S. | Chief Executive Officer |
| Dr. Edmund Kemp Waller FACP, M.D., Ph.D. | Chairman and Chief Scientific Officer |
| Mark Andrew Licciardo B Bus (Acc), FCIS, FGIA, GAICD, GradDip CSP | Company Secretary |